Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Algernon Pharmaceuticals Inc. is a biotechnology company focused on developing novel therapies for a range of medical conditions, including chronic pain and neurodegenerative diseases. The company's unique approach involves repurposing existing drugs, which may provide a faster path to market and lower development costs compared to traditional drug discovery.
Algernon Pharmaceuticals primarily generates revenue through partnerships and collaborations with larger pharmaceutical companies for the development of its drug candidates. The company leverages its expertise in drug repurposing to reduce time and costs associated with bringing new therapies to market.
Clinical trial results for its lead drug candidates, such as NP-120 (Ifenprodil)
Partnership announcements with larger pharmaceutical companies
Regulatory approvals or setbacks in drug development
Market sentiment towards biotechnology sector trends
Regulatory changes that could impact drug approval processes
Technological disruption in drug development methodologies
Emergence of new competitors in the drug repurposing space
Advancements in alternative therapies that could overshadow Algernon's offerings
High cash burn rate with no current revenue generation
Dependence on external funding for ongoing operations
low - The biotechnology sector is generally less sensitive to economic cycles as healthcare spending remains relatively stable regardless of economic conditions.
Interest rates affect the company's cost of capital for financing drug development. Higher rates could increase financing costs, impacting the ability to fund ongoing trials.
minimal - The company has no debt, reducing its exposure to credit conditions.
growth - Investors looking for high-risk, high-reward opportunities in the biotechnology sector.
high - The stock has exhibited significant volatility, particularly around clinical trial announcements and market sentiment shifts.